MilliporeSigma unveils new viral vector facility
Second Carlsbad location expected to double CDMO’s production capacity
MilliporeSigma, a life science business of Merck, has opened its second Carlsbad, CA-based facility, expanding its contract development and manufacturing organization (CDMO) footprint. According to company officials, this new $110 million, 140,000-square-foot facility will more than double MilliporeSigma’s existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy.
As mentioned earlier, this is the CDMO’s second Carlsbad facility dedicated to cell and gene therapy. There are a total of 30 cleanroom suites between both centers to support all aspects of manufacturing, ranging from small- to large-scale clinical and commercial production.
“We are continuing to invest in solving cell and gene therapy challenges in development and manufacturing, working alongside drug developers to industrialize, scale and accelerate the path to deliver therapies to patients,” notes Matthias Heinzel, member of the executive board and CEO, life science, Merck KGaA, Darmstadt, Germany.
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
New UK Consortium Obtains $1.34M Grant to Launch Automated Cell Therapy Manufacturing Platform
July 15th 2025Cellular Origins, CGT Catapult, and Resolution Therapeutics partner up to design a fully automated, scalable CGT manufacturing solution, with the goal of accelerating patient access to cell therapies.
